Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results



Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth
                 Quarter And Year-End 2012 Financial Results

Conference Call and Webcast Scheduled For Friday, February 8, 2013

PR Newswire

SAN DIEGO, Feb. 1, 2013

SAN DIEGO, Feb. 1, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq:
NBIX) announced today that the Company will report its fourth quarter and
year-end 2012 financial results before the Nasdaq market opens on Friday,
 February 8, 2013.  Neurocrine will then host a  live conference call and
webcast to discuss its financial results and provide a Company update Friday
morning, February 8, 2013 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).

Participants can access the live conference call by dialing 866-952-1906 (US)
or 785-424-1825 (International) using the conference ID: NBIX. The call can
also be accessed via the webcast through the Company's website at
http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on
this announcement please contact the Investor Relations Department at
Neurocrine Biosciences at (858) 617-7600.  A replay of the conference call
will be available approximately one hour after the conclusion of the call by
dialing 800-388-6197 (US) or 402-220-1115 (International) using the conference
ID: NBIX. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on
neurological and endocrine diseases and disorders. Our product candidates
address some of the largest pharmaceutical markets in the world, including
endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders,
pain, diabetes, insomnia, and other neurological and endocrine-related
diseases and disorders.  Neurocrine Biosciences, Inc. news releases are
available through the Company's website via the internet at
http://www.neurocrine.com.

SOURCE Neurocrine Biosciences, Inc.

Website: http://www.neurocrine.com
Contact: Neurocrine Biosciences, Investor Relations, +1-858-617-7600
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement